Drug Approval | December 23, 2023
Zydus Lifesciences' API site in Ahmedabad. receives 6 observations from USFDA
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
The inspection has concluded successfully on 1st September 2023 without any critical/major observation
Eris Lifesciences enters into term loan agreement with Citi Bank
The company has reported total income of Rs. 75.26 crores during the period ended June 30, 2023
Astec LifeSciences has reported total income of Rs. 144.55 crores during the period ended June 30, 2023
Eris Lifesciences has reported total income of Rs. 403.80 crores during the period ended March 31, 2023
He has over two decades of leadership experience as an innovative strategic planner in finance diligence
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
To enable company to be future-ready by tapping potential in CDMO space
The upcoming portfolio of respiratory products aims to provide effective solutions for a range of respiratory conditions
Subscribe To Our Newsletter & Stay Updated
